Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency

Piotr Ponikowski, Dirk J. Van Veldhuisen, Josep Comin-Colet, Georg Ertl, Michel Komajda, Viacheslav Mareev, Theresa McDonagh, Alexander Parkhomenko, Luigi Tavazzi, Victoria Levesque, Claudio Mori, Bernard Roubert, Gerasimos Filippatos, Frank Ruschitzka, Stefan D. Anker

Research output: Contribution to journalArticlepeer-review

Abstract

Aim The aim of this study was to evaluate the benefits and safety of long-term i.v. iron therapy in iron-deficient patients with heart failure (HF). Methods and results CONFIRM-HF was a multi-centre, double-blind, placebo-controlled trial that enrolled 304 ambulatory symptomatic HF patients with left ventricular ejection fraction 45%, elevated natriuretic peptides, and iron deficiency (ferritin

Original languageEnglish
Pages (from-to)657-668
Number of pages12
JournalEuropean Heart Journal
Volume36
Issue number11
DOIs
Publication statusPublished - Mar 14 2015

Keywords

  • Ferric carboxymaltose
  • Heart failure
  • Iron deficiency

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency'. Together they form a unique fingerprint.

Cite this